Revised SPC: Kisqali (ribociclib) tablets
SPC updated with warnings regarding risk of interstitial lung disease and pneumonitis and related dose modification recommendations including dose interruption, reduction or discontinuation depending on severity. Patients should be monitored for hypoxia, cough and dyspnoea.
Source:
electronic Medicines compendium